The combination of venetoclax and rituximab is known as VenR. 

When are Venetoclax + Rituximab Used?

The indication for VenR in CLL/SLL is for the treatment of adult patients with CLL/SLL who have received at least one prior therapy. VenR is a fixed-duration therapy, typically given for 24 months and then discontinued.

If you are receiving venetoclax as a second-line therapy, it's advisable to check if your insurance allows the substitution of rituximab for obinutuzumab. CLL specialists often recommend this based on data showing obinutuzumab to be more effective than rituximab in reducing CLL cells.

For more information about insurance coverage and obinutuzumab in second-line treatment with venetoclax, click here. 

How are Venetoclax + Rituximab Administered? 

After you have finished your 5-week venetoclax ramp-up dosing, you’ll receive one rituximab infusion on the first day of each month for 6 months (6 infusions in total).